Olema Pharmaceuticals, Inc.
NASDAQ:OLMABiotechnology
-$0.26 today
- Market cap
- $632.52M
- Beta
- 2.00
- P/E (TTM)
- -5.1
- EPS (TTM)
- -$1.80
Volume 1.27M
Average 1.27M
Returns on capital
Olema Pharmaceuticals, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-33.9%
avg -14.1%
ROIC
-37.0%
avg 10.2%
ROA
-30.5%
avg -438.7%
Analysis
ROA is currently the strongest return metric at -30.5% versus its period average of -438.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Sean Bohen | President, Chief Executive Officer & Director | USD 1.18M | 59 | 275.00K | 0.31% |
Naseem Zojwalla | Chief Medical Officer | USD 777.97K | 53 | 106.25K | 0.12% |
Shawnte Mitchell | Chief Legal Officer & Corporate Secretary | USD 664.75K | 48 | 0 | <0.01% |
David C. Myles | Chief Scientific Officer | USD 200K | 63 | 106.25K | 0.12% |
Jason O'Byrne | CFO, Principal Financial Officer & Accounting Officer | — | 57 | 650.00K | 0.74% |
Julie Dexter | Senior Vice President & Head of People | — | — | — | — |
Kamesh Kuchimanchi | Senior Vice President of Regulatory Affairs & Quality Assurance | — | — | — | — |
Mark Shilkrut | Senior Vice President of Clinical Development | — | — | — | — |
Richard Hernandez | Senior Vice President of Clinical Development Operations | — | — | — | — |
Courtney O'Konek | Vice President of Corporate Communications | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 1, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
25
$24.74M
Net Transaction Value
−$24.74M
Net selling
Most Active
Myles David C.
8 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jul 24, 26Jul 24, 2026 | Harmon Cyrus Direct | Sell | $146.4K$146,425.00 |
| Jul 23, 26Jul 23, 2026 | Harmon Cyrus Direct | Sell | $144.7K$144,737.50 |
| Mar 4, 26Mar 4, 2026 | Mitchell Shawnte Direct | Sell | $600.6K$600,599.75 |
| Mar 4, 26Mar 4, 2026 | Mitchell Shawnte Direct | Sell | $5.8K$5,752.77 |
| Mar 3, 26Mar 3, 2026 | Mitchell Shawnte Direct | Sell | $345.2K$345,150.00 |
| Jan 20, 26Jan 20, 2026 | Harmon Cyrus Direct | Sell | $268.8K$268,800.00 |
| Jan 15, 26Jan 15, 2026 | Kovacs Shane William Charles Direct | Sell | $2.9M$2,873,000.00 |
| Jan 14, 26Jan 14, 2026 | Myles David C. Direct | Sell | $428.9K$428,914.20 |
| Jan 14, 26Jan 14, 2026 | Myles David C. Direct | Sell | $1M$1,014,736.97 |
| Jan 14, 26Jan 14, 2026 | Harmon Cyrus Direct | Sell | $101.6K$101,599.68 |
1–10 of 25
Summary
Insiders reported 0 buys worth $0.00 and 25 sells worth $24.74M over the last 12 months. That adds up to net selling of $24.74M. Myles David C. was the most active insider with 8 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Olema Pharmaceuticals, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about OLMA's management, answered from reported figures.
Who manages OLMA?
Olema Pharmaceuticals, Inc. (OLMA) lists 10 active executives. The top listed executive is Sean Bohen, President, Chief Executive Officer & Director.
Are OLMA insiders buying or selling?
Recent insider activity shows net buying of $7.38M.
Continue the stock analysis
Jump to another research area for this company.